相关实验视频

Updated: Sep 12, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

在骨髓瘤中SIRPA,BTN3A1和TDO2:从综合的基因组和药物基因组数据中获得治疗意义的预后三位一体

Han-Jing Zhang^1,2, Zhi-Jun Yang¹, Wen Huang¹

¹Department of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Journal of orthopaedic surgery and research

|August 7, 2025

概括

这项研究确定了BTN3A1,SIRPA和TDO2免疫检查点作为骨髓瘤 (OS) 的关键预后生物标志物. 这些标志物可以预测患者的治疗结果和对氨酸urea和dcetaxel等治疗的潜在反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物标志物发现发现

背景情况:

骨髓瘤 (OS) 中免疫检查点的预后影响尚不清楚.
缺乏可靠的生物标志物阻碍了个性化治疗和OS的结果预测.
免疫检查点在瘤免疫逃避和治疗反应中起着至关重要的作用.

研究的目的:

调查骨髓瘤中特定免疫检查点 (BTN3A1,SIRPA,TDO2) 的预后价值.
根据这些免疫检查点,开发出基于这些免疫检查点的预后风险模型.
探索这些免疫检查点与药物敏感性之间的相关性.

主要方法:

利用了来自TARGET数据库的数据和临床后续数据.
进行了单变Cox回归和最小绝对收缩和选择操作员 (LASSO) 分析.
开发了三种免疫检查点遗传预后风险模型,并进行了药物敏感性分析.

主要成果:

BTN3A1,SIRPA和TDO2被确定为骨髓瘤的显著预后指标.
开发的风险模型显示了临床亚组的不同预后影响.
在BTN3A1,SIRPA,TDO2和氨酸urea和dcetaxel的疗效之间发现了相关性.

结论:

建立了一个使用免疫检查点作为骨髓瘤预后生物标志物的框架.
在临床队列中,SIRPA显示出显著的预后价值,表明其作为免疫治疗点的潜力.
研究结果支持免疫检查点在增强骨髓瘤患者个性化治疗策略方面的作用.

关键词:

免疫检查站免疫检查站免疫疗法是一种免疫疗法.骨质肉瘤骨质肉瘤是什么预测预后预测预测塞尔帕斯 (SIRPA) 是一个.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...